Predictors of long-term increase in CD4+cell counts in human immunodeficiency virus - Infected patients receiving a protease inhibitor - Containing antiretroviral regimen

Journal of Infectious Diseases

Volumn 185, Issue 4, 2002, Pages 471-480

  Le Moing, Vincent ^a,c   Thiébaut, Rodolphe ^c   Chêne, Geneviève ^c   Leport, Catherine ^a   Cailleton, Valérie ^e   Michelet, Christian ^f   Fleury, Hervé ^d   Herson, Serge ^b   Raffi, François ^g  

^a Service des Maladies Infectieuses et Tropicales   (United States)

^b BICHAT HOSPITAL   (France)

^c PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^d HÔPITAL PELLEGRIN   (France)

^e Institut Nationale de Santé   (France)

^f PONTCHAILLOU UNIVERSITY HOSPITAL   (France)

^g HÔTEL DIEU   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN; INDINAVIR; NELFINAVIR; PROTEINASE INHIBITOR; RITONAVIR; SAQUINAVIR; VIRUS RNA;

ADULT; ANTIVIRAL ACTIVITY; ARTICLE; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; TREATMENT FAILURE; TREATMENT OUTCOME;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; FEMALE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; MALE; PATIENT COMPLIANCE; PROSPECTIVE STUDIES; RNA, VIRAL;

EID: 0037083230     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/338929     Document Type: Article

References (33)

1. Modeling changes in CD4-positive T-lymphocyte counts after the start of highly active antiretroviral therapy and the relation with risk of opportunistic infections: The Aquitaine Cohort, 1996-1997
2. Use of changes in plasma levels of human immunodeficiency type 1 RNA to assess the clinical benefit of antiretroviral therapy
3. Relations among CD4 lymphocyte count nadir, antiretroviral therapy, and HIV-1 disease progression: Results from the EuroSIDA study
4. Clinical outcome of patients with HIV-1 infection according to immunologic and virologic response after six months of highly active antiretroviral therapy
5. Determinants of sustainable CD4 lymphocyte count increases in response to antiretroviral therapy
6. Highly active antiretroviral therapy including protease inhibitors does not confer a unique CD4 cell benefit
7. Determinants of paradoxical CD4 cell reconstitution after protease inhibitor - Containing antiretroviral regimen
8. Long-term immunological response in HIV-1 - Infected subjects receiving potent antiretroviral therapy
9. +T cell response after virologic failure of protease inhibitor - Based regimens in patients with human immunodeficiency virus infection
10. The relationship between virus load response to highly active antiretroviral therapy and change in CD4 cell counts: A report from the Women's Interagency HIV study
11. Full suppression of viral load is needed to achieve an optimal CD4 cell count response among patients on triple drug antiretroviral therapy
12. Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: A prospective cohort study
13. Highly active antiretroviral therapy in a large urban clinic: Risk factors for virologic failure and adverse drug reactions
14. HIV RNA and CD4 cell count response to protease inhibitor therapy in an urban AIDS clinic: Response to both initial and salvage therapy
15. CD4-cell count in HIV-1 - Infected individuals remaining viraemic with highly active antiretroviral therapy (HAART)
16. Discrepant responses to triple combination antiretroviral therapy in advanced HIV disease
17. Clinical and immunologic response without decrease in virus load in patients with AIDS after 24 months of highly active antiretroviral therapy
18. Definition of virological response and the type of assay used for quantification of viral load may influence the proportion of responders to antiretroviral therapy
19. Predictors of virological rebound after early virological response in a cohort of HIV-1 - Infected patients initiating a protease inhibitor - Containing regimen
20. +T cell homeostasis and function in advanced HIV disease
21. Random effects models for longitudinal data
22. A new look at the statistical model identification
23. 1993 Revised classification system for HIV infection and expanded case definition for AIDS among adolescents and adults
24. Clinical, biologic, and behavioral predictors of early immunologic and virologic response in HIV-infected patients initiating protease inhibitors
25. Clinical progression, survival, and immune recovery during antiretroviral therapy in patients with HIV-1 and hepatitis C virus coinfection: The Swiss HIV Cohort study
26. Hepatitis C virus in lymphoid cells of patients coinfected with human immunodeficiency virus type 1
27. Time to initiation of antiretroviral therapy: Impact on HIV-1 viraemia
28. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection
29. Antiretroviral therapy in adults: Updated recommendations of the International AIDS Society - USA Panel
30. Clinical progression of HIV-1 infection according to the viral response in the first year of antiretroviral treatment
31. +T cell counts despite virologic failure of protease inhibitor - Containing antiretroviral combination therapy
32. Concorde: MRC/ANRS randomised double-blind controlled trial of immediate and deferred zidovudine in symptom-free HIV infection
33. Mechanisms of virologic failure in previously untreated HIV-infected patients from a trial of induction-maintenance therapy